Quick answers
- What is Anoro Ellipta?
- Anoro Ellipta is a brand name of Umeclidinium bromide and vilanterol trifenatate, a prescription medicine. The FDA NDC Directory lists 1 Anoro Ellipta product in 1 strength and form.
- Who makes Anoro Ellipta?
- Glaxosmithkline holds the FDA application for Anoro Ellipta (NDA203975, approved December 18, 2013).
- Is there a generic or store brand of Anoro Ellipta?
- Yes. The FDA NDC Directory lists 1 other product with the same active ingredients, strength and form as a Anoro Ellipta product, 1 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Anoro Ellipta?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Anoro Ellipta strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Anoro Ellipta been recalled?
- FDA enforcement reports list 1 recall of Anoro Ellipta products; the newest started December 12, 2023. A recall usually concerns specific lots, not every product.
What Anoro Ellipta is
Each Anoro Ellipta product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Umeclidinium bromide and vilanterol trifenatate · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| umeclidinium bromide 62.5 ug · vilanterol trifenatate 25 ug powder (respiratory (inhalation)) | Anoro Ellipta | 1 product, 1 company | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Umeclidinium bromide and vilanterol trifenatate →
FDA approval
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| NDA203975 | Glaxosmithkline | December 18, 2013 | 1 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| umeclidinium bromide 62.5 ug · vilanterol trifenatate 25 ug powder | Brand: Anoro Ellipta | $7.80–$8.03 per unit 2 packages, lowest to highest Generic of the same strength and form: $4.94 per unit |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Anoro Ellipta
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Anoro Ellipta products.
- GlaxoSmithKline LLC1 product
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
December 12, 2023 · Class III · Terminated · D-0160-2024
Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification
ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) 62.5 mcg/25mcg. 1 inhaler contains 30 doses (60 blisters total), Rx Only, Manufactured by GlaxoSmithKline Durham, NC 27701. NDC 0173-0869-10 — GlaxoSmithKline LLC
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.